Immune Therapeutics, Inc. (OTCMKTS:IMUN) Files An 8-K Other Events
Item 8.01 Other Events
On May 22, 2017, Immune Therapeutics, Inc., a Florida corporation
(the Company) issued a press release announcing that it has
received NAFDAC (National Agency for Food and Drug Administration
and Control) approval to market and distribute
LodonalTM in Nigeria. The press release is attached
hereto.
Item 9.01 Financial Statements and Exhibits.
(d) Exhibits. The following exhibits are filed herewith.
| Exhibit No. | Description | |
| 99.1 | Press Release |
About Immune Therapeutics, Inc. (OTCMKTS:IMUN)
Immune Therapeutics, Inc. is a biotechnology company. The Company is involved in the manufacturing, distribution and marketing of therapies to combat chronic, life-threatening diseases through the activation and modulation of the body’s immune system using its patented immunotherapy. The Company’s products and immunotherapy technologies are designed to improve the treatment of cancer, infections, such as human immunodeficiency virus (HIV)/acquired immuno deficiency syndrome (AIDS), chronic inflammatory diseases and autoimmune diseases. Its technology platform is built on various immunotherapies, such as Low Dose Naltrexone (LDN) and Methionine-Enkephalin (MENK). Its technology offers treatment for a range of cancers. The Company’s clinical programs involve immunotherapy with Methionine-Enkephalin (MENK) (sometimes referred to as opioid growth factor) and its Low Dose Naltrexone (LDN) product or LodonalTM, which stimulates the immune system even in patients with advanced cancer. Immune Therapeutics, Inc. (OTCMKTS:IMUN) Recent Trading Information
Immune Therapeutics, Inc. (OTCMKTS:IMUN) closed its last trading session down -0.0055 at 0.0590 with 1,913,347 shares trading hands.
